{"id":753016,"date":"2023-05-01T08:56:26","date_gmt":"2023-05-01T12:56:26","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/"},"modified":"2023-05-01T08:56:26","modified_gmt":"2023-05-01T12:56:26","slug":"athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/","title":{"rendered":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference"},"content":{"rendered":"

<\/p>\n

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference<\/b><\/p>\n

CLEVELAND–(BUSINESS WIRE<\/a>)–
\nAthersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae<\/sup> (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care\u2019s (CTTACC) conference, \u201cCellular Therapies and Transfusion Medicine in Trauma and Critical Care,\u201d from May 8-11, 2023 in Scottsdale, Arizona.<\/p>\n

\nPresented by the University of California San Francisco and Colorado State University, this conference is the fifth in a series of conferences supporting the development and translation of novel therapies in trauma and critical care medicine, a field with limited therapeutic options. This conference will bring together the expertise and input of cell therapy companies, clinicians, basic scientists, industry, FDA, NIH, AABB, DARPA, BARDA and DOD representatives to discuss current research and existing barriers in the translation of these novel therapies in trauma and critical care medicine. Previous conferences have resulted in multiple cross-disciplinary collaborations and grants for pre-clinical studies and clinical trials.<\/p>\n

\nDr. Willie Mays, Executive Vice President and Head of Regenerative Medicine and Neuroscience Programs, has been invited to participate in this conference. On Tuesday, May 9th<\/sup>, he will be moderating a session titled, \u201cCellular and Novel Therapeutics in Neurotrauma and Polytrauma,\u201d which will focus on novel blood and cell therapies for traumatic brain injury (TBI) and spinal cord injury (SCI).<\/p>\n

\n\u201cAthersys\u2019 primary focus at this time is the clinical development of our proprietary cell therapy product, MultiStem, and its ability to treat and enhance recovery in patients suffering from acute severe injuries such as stroke and trauma,\u201d commented Dr. Mays. \u201cOpportunities to collaborate with other industry experts and advance the scientific understanding of novel therapies, like our MultiStem therapy, is critical for the clinical translation of cellular therapies now and in the future. I look forward to participating in this conference as its mission directly aligns with that of Athersys, to help patients in the acute care setting where there is an unmet medical need due to the limitations in standard of care.\u201d<\/p>\n

\nThe following are specific details regarding Dr. Mays\u2019 participation in the Cellular Therapies and Transfusion Medicine in Trauma and Critical Care conference:<\/p>\n\n\n\n\n\n
\n

\nEvent:<\/p>\n<\/td>\n

\n

\nSession 3 | Cellular and Novel Therapeutics in Neurotrauma and Polytrauma<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate:<\/p>\n<\/td>\n

\n

\nTuesday, May 9th, 2023<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime:<\/p>\n<\/td>\n

\n

\n1:15 p.m. ET<\/p>\n<\/td>\n<\/tr>\n

\n

\nLocation:<\/p>\n<\/td>\n

\n

\nOmni Scottsdale Resort & Spa, Scottsdale, Arizona<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nPlease visit https:\/\/cttacc.org\/<\/a> for additional information and registration.<\/p>\n

About Athersys<\/b><\/p>\n

\nAthersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem\u00ae<\/sup> cell therapy product, a patented, adult-derived \u201coff-the-shelf\u201d stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com<\/a> and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com<\/a> and on our social media accounts. Follow Athersys on Twitter at www.twitter.com\/athersys<\/a>. Information that we may post about the Company on our website and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

About MultiStem\u00ae<\/sup><\/b><\/p>\n

\nMultiStem\u00ae<\/sup> (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy\u2019s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique “off-the-shelf” stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230501005015\/en\/<\/a><\/span><\/p>\n

Athersys
\n<\/b>
Ellen Gurley
\n
Manager of Corporate Communications and Investor Relations
\n
ir@athersys.com<\/a><\/p>\n

LHA Investor Relations
\n<\/b>
Tirth T. Patel
\n
212-201-6614
\n
tpatel@lhai.com<\/a><\/p>\n

KEYWORDS:<\/b> Arizona Ohio United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Science Neurology Stem Cells Biotechnology Research Pharmaceutical Health Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference CLEVELAND–(BUSINESS WIRE)– Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care\u2019s (CTTACC) conference, \u201cCellular Therapies and Transfusion Medicine in Trauma and Critical Care,\u201d from May 8-11, 2023 in Scottsdale, Arizona. Presented by the University of California San Francisco and Colorado State University, this conference is the fifth in a series of conferences supporting the development and translation of novel therapies in trauma and critical care medicine, a field with limited therapeutic options. This conference will bring together the expertise and input of cell … <\/p>\n

Continue reading “Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-753016","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAthersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference CLEVELAND–(BUSINESS WIRE)– Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care\u2019s (CTTACC) conference, \u201cCellular Therapies and Transfusion Medicine in Trauma and Critical Care,\u201d from May 8-11, 2023 in Scottsdale, Arizona. Presented by the University of California San Francisco and Colorado State University, this conference is the fifth in a series of conferences supporting the development and translation of novel therapies in trauma and critical care medicine, a field with limited therapeutic options. This conference will bring together the expertise and input of cell … Continue reading "Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T12:56:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference\",\"datePublished\":\"2023-05-01T12:56:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/\"},\"wordCount\":897,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/\",\"name\":\"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-05-01T12:56:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference - Market Newsdesk","og_description":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference CLEVELAND–(BUSINESS WIRE)– Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) cell therapy for critical care indications, announced today their participation in the Cellular Therapeutics in Trauma and Critical Care\u2019s (CTTACC) conference, \u201cCellular Therapies and Transfusion Medicine in Trauma and Critical Care,\u201d from May 8-11, 2023 in Scottsdale, Arizona. Presented by the University of California San Francisco and Colorado State University, this conference is the fifth in a series of conferences supporting the development and translation of novel therapies in trauma and critical care medicine, a field with limited therapeutic options. This conference will bring together the expertise and input of cell … Continue reading \"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-01T12:56:26+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference","datePublished":"2023-05-01T12:56:26+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/"},"wordCount":897,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/","name":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-05-01T12:56:26+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230501005015r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/athersys-to-participate-in-the-cellular-therapies-and-transfusion-medicine-in-trauma-and-critical-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=753016"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/753016\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=753016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=753016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=753016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}